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Abstract
Objective—To assess the continuity of care and outcome of pediatric HIV prevention, testing,
and treatment services, focusing on early infant diagnosis with DNA PCR.
Design—A retrospective observational cohort.
Methods—Maternal HIV antibody, infant HIV DNA PCR test results, and outcome data from
HIV-infected infants from the prevention of mother-to-child transmission, early infant diagnosis,
and pediatric HIV treatment programs operating in Lilongwe, Malawi between 2004 and 2008
were collected, merged and analyzed.
Results—Of the 14,669 pregnant women who tested HIV antibody positive, 7,875 infants
(53.7%) received HIV DNA PCR testing. One thousand eighty-four infants (13.8%) were HIV-
infected. 320 (29.5%) children enrolled into pediatric HIV care, with 202 (63.1%) at the Baylor
Center of Excellence. Among these, antiretroviral therapy was initiated on 110 infants (54.5%)
whose median age was 9.1 months (interquartile range, 5.4 to 13.8) and a median of 2.5 months
(interquartile range, 1.4 to 9.2) after HIV clinic registration. Sixty-nine HIV-infected infants
(34.2%) died or were lost by December 2008. Initiation of antiretroviral therapy increased the
likelihood of survival seven-fold (odds ratio, 7.1; 95% confidence interval, 3.68 -13.70).
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Conclusions—Separate programs for maternal and infant HIV prevention and care services
demonstrated high attrition rates of HIV-exposed and HIV-infected infants, elevated levels of
mother-to-child transmission, late infant diagnosis, delayed pediatric antiretroviral therapy
initiation, and high HIV-infected infant mortality. Antiretroviral therapy increased HIV-infected
infant survival, emphasizing the urgent need for improved service coordination and strategies that
increase access to infant HIV diagnosis, improve patient retention, and reduce antiretroviral
therapy initiation delays.
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Background
High rates of vertical HIV transmission, late diagnosis of pediatric HIV infection, and high
early pediatric HIV-related mortality continue despite the scale-up of prevention of mother-
to-child transmission (PMTCT), early infant diagnosis (EID) with DNA PCR, and pediatric
antiretroviral therapy (ART) [1][2]. Inaccessibility and inadequate utilization of HIV
services results in large numbers of unidentified, HIV-exposed and HIV-infected children.
Globally, an estimated 420,000 new pediatric HIV infections occur annually, with the
mortality of untreated infants approaching 50% by two years of age [3][4].
Malawi, a sub-Saharan African country with over 14 million people [5], reports an antenatal
HIV prevalence of 15% in Lilongwe [6], and estimates that 90,000 HIV-infected children
are living within the country [3]. Although PMTCT programs have expanded nationally
such that 90% of facilities have antenatal care (ANC) testing services available as of the
March 2010, low enrollment and high attrition rates pose challenges [7-9]. A national ART
scale-up initiated in 2004 improved adult HIV treatment coverage to approximately 45% of
eligible; however, pediatric HIV care has lagged [10]. Specifically, children account for 9%
of HIV-infected individuals ever started on ART in Malawi, well below recommendations
[11-13].
While previous studies described PMTCT, EID, and pediatric HIV care in isolation [14-17],
few studies have assessed the continuum of mother-infant HIV service utilization. This
study retrospectively reviewed data from the PMTCT, EID, and pediatric HIV care sites
operating in Lilongwe since 2004 in order to determine the numbers of infants tested for
HIV, to quantify the timing of infant diagnosis, clinic enrollment, and treatment initiation,
and to analyze the outcome of HIV-infected infants found at ART clinics. Based upon this
evaluation, we offer recommendations to address identified gaps in PMTCT and EID
provision.
Materials and Methods
Study Setting and Population
ANC testing—The University of North Carolina (UNC) Project in Malawi implemented a
PMTCT program in 2002 at Bwaila Hospital, the largest government ANC facility in
Lilongwe District and three Lilongwe district health centers (Area 18, Area 25 and Kawale)
[7]. Nurses issued an identification number, collected patient information, and conducted
HIV antibody tests on all women at the initial ANC visit. Subsequently, HIV-infected
women had a CD4 count analysis. All HIV infected women with WHO stage 3 or 4 disease
or a CD4 count < 250 cells were ART eligible and referred for care. HIV-infected ART
ineligible pregnant women were given single dose nevirapine and advised to take the
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medication during labor, as well as to administer a single dose to their newborn infant, per
national guidelines.
EID and follow-up of exposed infants—Infant plasma HIV DNA PCR testing at six
weeks of age began in 2004 at ANC clinics as part of the UNC Project PMTCT Program [7].
In mid-2007, EID, a Ministry of Health (MOH) program utilizing dried blood spot HIV
DNA PCR testing of HIV-exposed infants, was implemented in 7 pilot sites nationally
including the 4 ANC sites in Lilongwe, the Baylor College of Medicine-Abbott Fund
Children's Clinical Centre of Excellence (COE), and at Kamuzu Central Hospital (KCH), a
regional referral facility. All PCR testing used the Roche Amplicor.
In the EID program, infants of known HIV-infected mothers received DNA PCR testing at
six weeks of age, and mothers were instructed to return in one month to receive the results.
If the baby was DNA PCR negative but breastfeeding within six weeks of the test, the baby
was defined as HIV-exposed. All HIV-exposed infants were recommended to return to an
EID clinic or the Baylor COE on a monthly basis to receive cotrimoxazole preventive
therapy (CPT). At 6 months post-partum, mothers were advised to wean their child from
breastfeeding if they met World Health Organization (WHO) weaning criteria. Six weeks
after breastfeeding cessation a second, definitive HIV DNA PCR test was conducted on the
infant, with results available after one month. If DNA PCR negative, the baby was
considered HIV-uninfected, CPT was discontinued, and the infant was discharged. If the
infant became HIV-infected at any time, the child was verbally referred to an ART clinic.
Although the child's HIV status was noted in their health passport, the EID program did not
document referrals.Date of diagnosis was defined as the date of a patient's first positive
DNA PCR test.
The Breastfeeding, Antiretroviral and Nutrition (BAN) study began in April 2004 and also
included infant DNA PCR testing. Infants born to HIV-infected study participants were
tested at birth, 2, 12, 28, and 48 weeks of age, with HIV-infected infants referred for
treatment [18].
Non-routine inpatient pediatric HIV testing at KCH was introduced in 2006. In early 2008,
the Baylor program implemented a routine opt-out HIV testing system for hospitalized
children at KCH, which included DNA PCR [16].
Pediatric HIV Care—Lighthouse Trust first offered pediatric ART at KCH in 2002. The
KCH pediatrics department operated a pediatric HIV clinic at KCH from 2004 until the
opening of the Baylor COE clinic in late 2006. Another Lighthouse clinic opened near
Bwaila Hospital, also late in 2006, providing a family centered approach although infants
less than 18 months were referred to the Baylor COE. Pediatric ART was also offered at the
Area 18, Area 25 and Kawale district health centers included in this study starting in early
2007. Registration data from Baylor COE is electronic while the health centers utilized
paper ART registers and master cards. ART eligibility in Malawi includes any child who has
a WHO stage 3 or 4 condition or CD4 percentage below age thresholds [19]. From
mid-2008, universal ART was available for children under 12 months of age [20]. First line
ART for children was stavudine/lamivudine/nevirapine.
Study design and data collection
We conducted a retrospective review of patient registers and electronic records of all
pregnant women HIV tested at four UNC-affiliated ANC clinics to determine the potential
number of HIV-exposed and HIV-infected children born and tested since 2004. Among the
identified infected infants, we conducted an analysis of characteristics and outcomes.
Routine MOH data from ANC registers, ART clinic registers and HIV testing records from
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the four UNC-affiliated ANC clinics and KCH were reviewed (Table 1). From 2004 until
mid 2007 when PMTCT/EID services were operated by UNC project, ANC nurses
documented HIV-infected infant data in logbooks and triplicate referral forms. The referral
form contained maternal and infant information. One copy remained in the ANC records and
two were given to the patient. One patient copy was for the ART clinic and the other was to
be returned to the UNC Project to confirm patient enrollment into care. Prior to the EID
program, HIV DNA PCR testing was performed in the UNC Project laboratory and entered
into an electronic information system. After transition of the EID program to the MOH, the
EID program utilized dried blood spot DNA PCR testing in the KCH laboratory only. Data
officers electronically entered maternal PMTCT information and data of all patients enrolled
in pediatric HIV clinics. The pediatric HIV clinics at the district health centers maintained
registers and mastercards for all HIV-exposed and infected children starting in 2007.
Additionally, the Baylor COE maintains an electronic record of all enrolled children. This
study was approved by the Malawi National Health Sciences Research Committee, the
University of North Carolina and the Baylor College of Medicine Institutional Review
Boards. Written or verbal consent was not required since this evaluation used existing data
sources.
Data Analysis
We merged all infant testing information into one database, and removed any duplicates. We
then linked each infant to their mother's ANC data using the PMTCT and BAN
identification numbers. Our combined mother and infant data was linked to Baylor COE
data using several identifiers. We required at least two matching factors and the absence of
conflicting factors to link the data. After ensuring for accuracy, we created a final table
devoid of identifiers and used SAS 9.2 (Cary, NC) for all analyses.
Pediatric outcome analysis was restricted to the children identified at the COE due to the
availability of an electronic database. All ART clinic outcomes conformed to the Malawi
national ART program; including: alive, died, lost to follow-up (LTFU), and transferred out.
When assessing mortality, we performed two sets of analyses: one in which LTFU and
Transferred out were censored and another where the outcomes LTFU and Died, and
Transferred Out and Alive were merged, respectively. We used bivariate analyses to
determine the relationship between survival outcome and the timing of diagnosis,
presentation to care, treatment initiation, and WHO stage at presentation. Differences in
overall survival probability curves were generated using cox-proportional hazards models
and displayed using Kaplan-Meier plots according to ART status initiation status.
Results
Of the 14,669 pregnant women who tested HIV antibody positive, there were 7,875 infant
HIV DNA PCR test results found, representing just over half of the HIV-exposed infants
identified by maternal records from the sampled ANC clinics (Table 2). Most HIV DNA
PCR tests were conducted through routine services 5506/7875 (70%) with the remainder of
testing through the BAN study. Of the infants DNA PCR tested, 13.8% were HIV-infected,
of whom less than one out of three enrolled into HIV care. Sixty-three percent of the infants
traced to care were found at the Baylor COE, with the remainder receiving care at the
district health centers (Table 2, Figure 1). The 6,794 HIV-exposed infants that were not HIV
tested or successfully traced account for potentially 938 HIV-infected, untreated infants
using this cohort's 13.8% vertical HIV transmission rate.
Of the 1,084 HIV-infected infants, 320 (29.5%) were traced to an ART clinic and 764
confirmed infected children were not linked to care. Among children arriving at the Baylor
COE, nearly 72% were identified as outpatients, with the remainder inpatients at the time of
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referral (Table 3). Infants referred from outpatient clinics were diagnosed and enrolled into
care at significantly younger ages than infants referred while hospitalized. Overall, the
median age at diagnosis was 3.0 months for all patients, 2.0 months for infants referred from
outpatient facilities, and 10.2 months for inpatient referrals (Table 3). Outpatient referrals
enrolled into ART clinics a median of 1.4 (IQR 0.8-2.5) months after diagnosis.
As of December 2008, only about half of the 221 infants who we successfully traced to the
Baylor COE had initiated ART, a median of 2.5 months after clinic registration (Table 3).
The median duration on ART was 7.4 months. Outpatient referrals began treatment at a
younger age compared to inpatient referrals; 8.3 versus 12.7 months. While we observed a
reduction in the delay to ART initiation each year, the proportion of infants starting ART did
not increase (Table 4). ART initiators were not significantly younger than non-initiators at
diagnosis (5.1 versus 6.9 months, p= 0.062), however they were younger at enrollment (6.4
versus 8.7 months, p= 0.010).
Sixty-nine HIV-infected infants in care at the COE died or were lost to follow up (34.2%) by
December 2008, with slightly more than one-third of these events (34.8%) occurring within
the first 3 months (Figure 1). Antiretroviral therapy increased the likelihood of survival
seven-fold (odds ratio, 7.1; 95% confidence interval, 3.68 -13.70; p<0.0001). We did not
find significant associations between survival and age at diagnosis, time from diagnosis to
enrollment, time from enrollment to ART initiation, or advanced WHO stage at presentation.
The findings were similar in our sensitivity analysis that censored for LTFU and Transfer
Out (data not shown).
Discussion
Large numbers of HIV-exposed infants in Lilongwe, Malawi did not access HIV testing.
Among HIV-infected infants, only 29.5% successfully enrolled into facilities providing
pediatric HIV services, with mortality rates remaining high despite successful linkage to a
care facility. Overall, this suggests PMTCT, EID, and pediatric ART services are not
sufficiently integrated, resulting in high default rates, elevated levels of vertical HIV
transmission, late infant HIV diagnosis, delayed pediatric ART initiation, and high HIV-
infected infant mortality.
Other studies evaluating PMTCT programs have previously reported high attrition rates after
initial maternal HIV diagnosis [21] [22] [23]. Our findings expand on this by highlighting
key components of PMTCT care from the infant's perspective, as well as the high mortality
rate of ART naïve, HIV-infected infants [24] [25]. It is important to note that our results
likely under-estimate infant mortality as we reported only the outcome of patients who
enrolled in HIV care facilities.
We only traced 320 HIV-infected infants to a pediatric ART clinic, with a majority found at
the Baylor COE, likely due to the gradual uptake of pediatric ART services at health centers
during this time period. The high attrition can be partly attributed to the absence of one
facility providing the full spectrum of maternal and infant HIV services on a daily basis,
along with the relative cost of transportation for a mostly impoverished patient population.
HIV-infected mothers may receive ANC and maternity at one location yet pediatric services
at Baylor COE were on a different campus. Prior studies have demonstrated the cost of
transport as a barrier to the retention of HIV-infected patients in care, and it is likely that it
similarly impedes infant HIV test result follow-up and subsequent program attrition,
particularly when care for the mother and infant are not at the same facility [26][27][8]. The
lack of consistent patient identification, coupled with the disjointed, multi-facility provision
of HIV services detrimentally affects retention. Suboptimal referral systems prevented
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tracing across the facilities and determining drop-out points. For example, verbal referral
systems prevented determining if patients failed to collect PCR results or failed to report to
clinic after being provided with results.
The identified patients are likely representative of HIV-infected Malawian infants that enter
care in Lilongwe, as this study was generated from operational data from all sites
implementing service during this time period. We acknowledge that some additional infants
may have been tested or arrived to care and were not captured due incompatible patient
identification numbers and suboptimal referral documentation. Missing infant test records,
lost results, and illegible referral forms challenged data collection efforts, overall program
monitoring, and patient and healthcare provider navigation of the maternal-child healthcare
system. Additionally, our data sources were not robust enough to identify women who may
have had HIV sero-conversion after their first ANC visit. Our findings may not be
representative of areas with lower HIV prevalence such as more rural locations or those with
less partner support. The additional activities support by the BAN study and the Baylor
community outreach programs likely increased the number of children accessing services.
At the time of our evaluation, EID was only available in 7 sites nationally. Currently, EID
has expanded to 14 of 28 districts covering 24% of PMTCT sites. However, given there are
only 3 PCR labs which still rely on manual techniques, the results of dried blood spot DNA
PCR testing are only available after one month. With expansion of the program, delays of
four months have been observed (HIV unit, Ministry of Health). We observed inefficiencies
in the EID system that affected test result availability, notably the unreliable transportation
of test results from the central laboratory to the clinical facility. Point of care infant HIV
testing, including rapid DNA PCR assays, bed-side p24 antigen testing, and quantitative
reverse transcriptase activity analyses [27] [28][29][30] could dramatically improve EID
systems by facilitating the immediate referral of HIV-infected infants, eliminating the need
for a separate visit to receive results. Alternatively, the novel use of cell phones to transmit
results from central labs to external clinics may improve communication of lab results in
Malawi.[31].
While ART improved infant survival, we noted delays in ART initiation by several months
after enrollment. The delay in ART initiation was influenced by the treatment guidelines of
the period, which recommended ART initiation for all HIV-infected infants based upon
clinical and/or immunologic criteria [19]. The WHO and MOH modified their
recommendations for ART eligibility to include all HIV-infected infants younger than 12
months in mid-2008 after data demonstrated efficacy of this strategy [20] [32]. This policy
change likely reduced the time to ART initiation that we observed in our cohort.
Importantly, our findings of high mortality in patients not initiating ART further support
these guidelines.
Delays in ART initiation may also stem from Baylor affiliated HIV clinics pre-ART
education requirements. While the Malawi ART program requires only a single pre-ART
education, one guardian and an understanding of the implications of ART [19], the Baylor
COE requires two pre-ART education sessions for caregivers and identification of a second
caregiver prior to initiating infant ART. While ART adherence education is a critical
component of successful pediatric ART treatment [33], it must be balanced with the
importance of timely ART initiation.
While the integration of PMTCT, EID, and pediatric HIV care programs has been a common
challenge throughout resource limited settings [34][17], our findings suggest that the
following five recommendations may improve PMTCT and pediatric HIV services.
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ART initiation in infants should be treated as medically urgent, given the rapid disease
progression and high mortality observed within this age group in the absence of ART.
Following the WHO guidelines, all HIV-infected infants under 12 months of age should
begin ART as soon as is feasible, with referral and care systems taking the necessary steps to
accommodate this urgency. Combining HIV education and ART adherence training into
enrollment visits or during hospitalization may allow ART initiation to occur earlier with
well-adjusted and informed guardians.
Recommendation 2
In lieu of restructuring the delivery of maternal and infant HIV services into one facility, we
recommend that a universal patient identification system be nationally implemented to allow
tracing of mother-infant pairs between PMTCT, EID, and pediatric HIV facilities.
Combined with standardized documentation within health passports, a universal
identification system would facilitate communication between PMTCT, EID, and pediatric
HIV sites and could help confirm arrival of referred patients. Moreover, such a system
would benefit tuberculosis control, immunization, and other national health programs. Novel
tracing strategies may ensure that mother-infant pairs are receiving the full continuum of
HIV services. One example, is the Baylor Tingathe outreach program which uses
community health workers to track mother infant pairs starting from the mother's diagnosis
at antenatal care until there is either a definitive negative diagnosis for the infant or positive
diagnosis and confirmed entry into clinical care with ART initiation. Preliminary results
from this program have demonstrated improved utilization of services and a dramatic
decrease in loss-to-follow-up of mothers and infants. [35,36].
Recommendation 3
We recommend routine provider initiated infant HIV antibody testing at all immunization
visits, starting at the sixth week of life in settings where HIV exposure documentation does
not exist or tracking mother-infant pairs is not feasible. While high proportions of Malawian
women deliver outside of formal healthcare facilities, most infants routinely access
immunization clinics [33]. Using a strategy of HIV antibody screening of all infants
attending the six-week immunization visit, followed by DNA PCR testing of those with
positive HIV antibody test results, has been demonstrated to be high yield, feasible, and
acceptable in South Africa [37,38]. The expansion of this strategy would be an effective
utilization of an existing, well functioning healthcare service to provide early post-natal
identification of HIV-exposed infants.
Recommendation 4
Routine inpatient pediatric HIV testing provides another critical avenue for the identification
of HIV-exposed and HIV-infected children who may have been missed in the early post-
natal period, or who acquired HIV later in infancy via breastfeeding. This strategy has been
demonstrated as a highly productive, viable, and acceptable approach in Malawi [16],
Zambia [39], and Uganda [40]. Furthermore, this is an effective strategy to diagnose
previously unidentified HIV-infected mothers as well as re-identify defaulted HIV-exposed
and HIV-infected children [16].
Recommendation 5
Infant HIV DNA PCR test results should be reported in two weeks or less if ART initiation
hinges on the result in order to prevent excessive infant mortality. Where DNA PCR testing
is not yet available or results are severely delayed, we recommend utilizing a clinical
diagnostic algorithm to determine ART eligibility in HIV antibody positive infants.
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Development of a valid, rapid point of care assay for infant HIV infection remains a high
priority for PMTCT and pediatric treatment programs.
While these recommendations should be interpreted within the context of national PMTCT,
EID, and pediatric HIV treatment programs, as well as in light of current PMTCT regimens
[42], they can likely be generalized given the HIV epidemiologic and program similarities
between sub-Saharan African countries. The implementation of these recommendations
would therefore represent a significant advancement for pediatric HIV prevention and care
programs throughout generalized HIV-epidemic, resource-limited settings.
Conclusion
This study demonstrated a high attrition rate of HIV-exposed and HIV–infected infants
between maternal and infant HIV care services, elevated levels of mother-to-child
transmission, delayed diagnosis and late ART initiation in HIV-infected infants, and high
subsequent mortality rates in HIV-infected, ART naïve infants enrolled into pediatric HIV
care in urban Malawi. Our findings suggest that establishing integrated PMTCT, EID, and
pediatric HIV care services along with implementing strategies to improve patient retention
and access to earlier infant testing and ART initiation would greatly improve outcomes for
HIV-infected infants in generalized epidemic, resource-constrained settings.
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Table 1
Sources of HIV-infected infant DNA PCR test results
Data Source Site Dates
Infant HIV test logbooks ANC clinics February 2004 – April 2007
Referral logbooks ANC clinics January 2005 – December 2008
BAN and PMTCT electronic laboratory results Bwaila ANC clinic August 2004 – December 2008
EID electronic database ANC clinics and Baylor COE April 2007 – December 2008
EID logbooks and master cards ANC clinics April 2007 – December 2008
Baylor COE electronic database Baylor COE October 2004 – December 2008
ART treatment registers District Health Centers January 2007- December 2008
Pediatric HIV clinic registers District Health Centers February 2007- December 2008
ART, antiretroviral therapy, BAN, Breastfeeding Antiretroviral and Nutrition study, PMTCT, Prevention of Mother to Child Transmission; EID,
early infant diagnosis; ANC, antenatal clinic; COE, Centre of Excellence













Braun et al. Page 14
Table 2
Summary of HIV-exposed and HIV-infected infant tracing from antenatal clinic to
pediatric ART Clinic, 2004-2008
Women HIV antibody tested 101,251
HIV-infected women, n/N (%) 14,669/101,251 (14.5%)
HIV-infected women receiving any PMTCT prophylaxis† 14,579/14,669 (99.2%)
 ART (stavudine/lamivudine/nevirapine) 1,284/14,669 (8.8%)
 Single dose NVP 13,295/14,669 (90.6%)
HIV-exposed infants receiving single dose NVP† 6,930/14,669 (47.2%)
Infants HIV DNA PCR tested, n/N (%) 7,875/14,669 (53.7%)
HIV-infected infants, n/N (%) 1,084/7,875 (13.8%)
HIV-infected infants traced to an ART clinic, n/N (%) 320/1,084 (29.5%)
HIV-infected infants traced to the Baylor COE, n/N (%) 202/320 (63.1%)
ART, antiretroviral; DNA, Deoxyribonucleic nucleic acid; PCR, polymerase chain reaction, COE, Center of Excellence
†
Received at ANC clinic, ingestion not verified.
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Table 3
Characteristics of HIV-infected infants traced to the Baylor COE stratified by point of entry.
All Infants (%) Outpatients (%) Inpatients (%) P-Value
Total clients traced,1 n/N (%) 202 (100.0) 145/202 (71.8) 57/202 (28.2) NS
 Females, n/N (%) 108/202 (53.0) 80/145 (55.2) 28/57 (49.1) NS
WHO stage at clinic enrollment, n/N (%)
 1 107/202 (53.0) 90/145 (62.1) 17/57 (29.8) NS
 2 19/202 (9.4) 11/145 (7.6) 8/57 (14.0) NS
 3 48/202 (23.8) 29/145 (20.0) 19/57 (33.3) NS
 4 13/202 (6.4) 7/145 (4.8) 6/57 (10.5) NS
 Not available 15/202 (7.4) 8/145 (5.5) 7/57 (12.3) NS
ART initiation, n/N (%) 110/202 (54.5) 83/145 (57.2) 27/57 (47.4) NS
Age < 12 months at ART initiation, n/N (%) 77/110 (70.0) 65/83 (78.3) 12/27 (44.4) NS
Outcome, n/N (%)
 Alive 120/202 (59.4) 88/145 (60.7) 32/57 (56.1) NS
 Death 43/202 (21.3) 27/145 (18.6) 16/57 (38.6) NS
 Loss to follow-up 26/202 (12.9) 20/145 (13.8) 6/57 (10.5)
 Transferred out 13/202 (6.4) 10/145 (6.9) 3/57 (5.3) NS
Age at diagnosis (mos, median (IQR)) 3.0 (0.5-8.6) 2.0 (0.2-3.9) 10.2 (6.5-15.7) <0.001
Age at enrollment (mos, median (IQR)) 5.5 (2.7 – 10.0) 4.2 (2.3-7.7) 10.0 (6.5-15.7) <0.001
ART initiators All (N=110) Outpatient (N=83) Inpatient (N=27) P-Value
Age at ART initiation (mos, median (IQR)) 9.1 (5.4-13.8) 8.3 (5.0-11.5) 12.7 (9.8-16.6) 0.009
Time from enrollment to ART initiation (mos, median (IQR)) 2.5 (1.4 – 5.2) 2.5 (1.2 – 5.6) 2.5 (1.5 – 5.2) NS
Time on ART (mos, median (IQR)) 7.4 (3.8 – 13.1) 7.8 (4.5 – 15.2) 5.4 (3.1 – 9.6) 0.0204
ART, antiretroviral therapy; mos, months; IQR, interquartile range; SD, standard deviation; NS, not significant, COE, Center of Excellence
1
Nineteen traced infants were excluded from outcomes analysis due to incomplete documentation.
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Table 4
Changes in Time to ART initiation among HIV-infected infants at Baylor COE by year
Year
% of ANC attendees tested for
HIV Infants enrolled
Infants initiated on ART (% of
total enrolled)
Mean (SD) time from enrollment to
ART initiation (months)
2005 93% 9 5 (55.6) 10.0 (11.6)
2006 99% 23 15 (65.2) 7.3 (6.2)
2007 99.5% 72 43 (59.7) 4.2 (3.4)
2008 99.8% 98 47 (48.0) 2.4 (1.6)
ART, antiretroviral therapy; COE, Center of Excellence; SD, standard deviation
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